PDL BioPharma Inc (NAS:PDLI) Stock Analysis

PDLI- NAS (USA) Also traded in: Germany
PDL BioPharma Inc

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$2.9

0(0%) Volume: 791,451 8:08PM EDT

Avg Vol (1m): 1,574,049

Warning! GuruFocus has detected 4 Severe Warning Signs with NAS:PDLI. Click here to check it out.

Market Cap : 446.06 M	Enterprise Value : 157.43 M	P/E (TTM) : 4.04	P/B : 0.52

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Also traded in: Germany

Financial Strength : 7/10

		vs industry	vs history
Cash-to-Debt	2.19	PDLI's Cash-to-Debt is ranked lower than 71% of the 1056 Companies in the Global Biotechnology industry. ( Industry Median: 73.06 vs. PDLI: 2.19 ) Ranked among companies with meaningful Cash-to-Debt only. =GURUF("PDLI","Cash-to-Debt")	PDLI' s Cash-to-Debt Range Over the Past 10 Years Min: 0.25 Med: 2.04 Max: No Debt Current: 2.19 0.25 - No Debt =GURUF("PDLI","Cash-to-Debt")
Equity-to-Asset	0.68	PDLI's Equity-to-Asset is ranked lower than 51% of the 770 Companies in the Global Biotechnology industry. ( Industry Median: 0.68 vs. PDLI: 0.68 ) Ranked among companies with meaningful Equity-to-Asset only. =GURUF("PDLI","Equity-to-Asset")	PDLI' s Equity-to-Asset Range Over the Past 10 Years Min: -1.85 Med: 0.68 Max: 0.97 Current: 0.68 -1.85 - 0.97 =GURUF("PDLI","Equity-to-Asset")
Debt-to-Equity	0.29	PDLI's Debt-to-Equity is ranked lower than 52% of the 488 Companies in the Global Biotechnology industry. ( Industry Median: 0.27 vs. PDLI: 0.29 ) Ranked among companies with meaningful Debt-to-Equity only. =GURUF("PDLI","Debt-to-Equity")	PDLI' s Debt-to-Equity Range Over the Past 10 Years Min: -4.55 Med: 0.29 Max: 3.48 Current: 0.29 -4.55 - 3.48 =GURUF("PDLI","Debt-to-Equity")
Debt-to-EBITDA	1.05	PDLI's Debt-to-EBITDA is ranked higher than 61% of the 213 Companies in the Global Biotechnology industry. ( Industry Median: 1.97 vs. PDLI: 1.05 ) Ranked among companies with meaningful Debt-to-EBITDA only. =GURUF("PDLI","Debt-to-EBITDA")	PDLI' s Debt-to-EBITDA Range Over the Past 10 Years Min: 0.46 Med: 1.12 Max: 2.65 Current: 1.05 0.46 - 2.65 =GURUF("PDLI","Debt-to-EBITDA")
Interest Coverage	8.72	PDLI's Interest Coverage is ranked lower than 87% of the 521 Companies in the Global Biotechnology industry. ( Industry Median: 10000.00 vs. PDLI: 8.72 ) Ranked among companies with meaningful Interest Coverage only. =GURUF("PDLI","Interest Coverage")	PDLI' s Interest Coverage Range Over the Past 10 Years Min: 4.85 Med: 12.37 Max: 19.15 Current: 8.72 4.85 - 19.15 =GURUF("PDLI","Interest Coverage")

Piotroski F-Score: 7
Altman Z-Score: 2.96
Beneish M-Score: -2.44
WACC vs ROIC	4.76% 17.31% WACC ROIC

Profitability & Growth : 6/10

		vs industry	vs history
Operating Margin %	58.34	PDLI's Operating Margin % is ranked higher than 96% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -98.02 vs. PDLI: 58.34 ) Ranked among companies with meaningful Operating Margin % only. =GURUF("PDLI","Operating Margin %")	PDLI' s Operating Margin % Range Over the Past 10 Years Min: 58.34 Med: 93.2 Max: 94.93 Current: 58.34 58.34 - 94.93 =GURUF("PDLI","Operating Margin %")
Net Margin %	36.63	PDLI's Net Margin % is ranked higher than 91% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -88.19 vs. PDLI: 36.63 ) Ranked among companies with meaningful Net Margin % only. =GURUF("PDLI","Net Margin %")	PDLI' s Net Margin % Range Over the Past 10 Years Min: 23.25 Med: 55.8 Max: 60.49 Current: 36.63 23.25 - 60.49 =GURUF("PDLI","Net Margin %")
ROE %	13.85	PDLI's ROE % is ranked higher than 86% of the 969 Companies in the Global Biotechnology industry. ( Industry Median: -40.23 vs. PDLI: 13.85 ) Ranked among companies with meaningful ROE % only. =GURUF("PDLI","ROE %")	PDLI' s ROE % Range Over the Past 10 Years Min: 8.79 Med: 72.89 Max: 1166.18 Current: 13.85 8.79 - 1166.18 =GURUF("PDLI","ROE %")
ROA %	8.90	PDLI's ROA % is ranked higher than 86% of the 1062 Companies in the Global Biotechnology industry. ( Industry Median: -32.55 vs. PDLI: 8.90 ) Ranked among companies with meaningful ROA % only. =GURUF("PDLI","ROA %")	PDLI' s ROA % Range Over the Past 10 Years Min: 5.71 Med: 38.25 Max: 77.05 Current: 8.9 5.71 - 77.05 =GURUF("PDLI","ROA %")
ROC (Joel Greenblatt) %	4054.74	PDLI's ROC (Joel Greenblatt) % is ranked higher than 98% of the 1021 Companies in the Global Biotechnology industry. ( Industry Median: -430.94 vs. PDLI: 4054.74 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. =GURUF("PDLI","ROC (Joel Greenblatt) %")	PDLI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years Min: 98.44 Med: 82080.42 Max: 1198273.12 Current: 4054.74 98.44 - 1198273.12 =GURUF("PDLI","ROC (Joel Greenblatt) %")
3-Year Revenue Growth Rate	-14.40	PDLI's 3-Year Revenue Growth Rate is ranked lower than 72% of the 604 Companies in the Global Biotechnology industry. ( Industry Median: 4.00 vs. PDLI: -14.40 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. =GURUF("PDLI","3-Year Revenue Growth Rate")	PDLI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years Min: -22 Med: 13.4 Max: 65.5 Current: -14.4 -22 - 65.5 =GURUF("PDLI","3-Year Revenue Growth Rate")
3-Year EBITDA Growth Rate	-22.00	PDLI's 3-Year EBITDA Growth Rate is ranked lower than 83% of the 722 Companies in the Global Biotechnology industry. ( Industry Median: 3.10 vs. PDLI: -22.00 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. =GURUF("PDLI","3-Year EBITDA Growth Rate")	PDLI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years Min: 0 Med: -15 Max: 202.9 Current: -22 0 - 202.9 =GURUF("PDLI","3-Year EBITDA Growth Rate")
3-Year EPS without NRI Growth Rate	-27.50	PDLI's 3-Year EPS without NRI Growth Rate is ranked lower than 87% of the 704 Companies in the Global Biotechnology industry. ( Industry Median: 4.20 vs. PDLI: -27.50 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. =GURUF("PDLI","3-Year EPS without NRI Growth Rate")	PDLI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years Min: 0 Med: -43.2 Max: 89.5 Current: -27.5 0 - 89.5 =GURUF("PDLI","3-Year EPS without NRI Growth Rate")

GuruFocus has detected 4 Warning Signs with PDL BioPharma Inc PDLI.

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

» PDLI's 30-Y Financials

Financials (Next Earnings Date: 2018-05-03)

Revenue & Net Income

Cash & Debt

Operating Cash Flow & Free Cash Flow

Operating Cash Flow & Net Income

» PDLI's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades

Q1 2017

Q2 2017

Q3 2017

Q4 2017

» Details

Insider Trades

Financial Reports

10-K Annual report [Section 13 and 15(d), not S-K Item 405]

2017/12/31

10-Q Quarterly report [Sections 13 or 15(d)]

2017/09/30

10-Q Quarterly report [Sections 13 or 15(d)]

2017/06/30

10-Q Quarterly report [Sections 13 or 15(d)]

2017/03/31

DEF 14A Other definitive proxy statements

2017/06/09

10-K Annual report [Section 13 and 15(d), not S-K Item 405]

2016/12/31

10-Q Quarterly report [Sections 13 or 15(d)]

2016/09/30

10-Q Quarterly report [Sections 13 or 15(d)]

2016/06/30

10-Q Quarterly report [Sections 13 or 15(d)]

2016/03/31

DEF 14A Other definitive proxy statements

2016/04/21

Latest Guru Trades with NAS:PDLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Select Gurus: | Basic | Premium

| Premium Plus

Guru	Date	Trades	Impact to Portfolio	Price Range * (?)	Current Price	Change from Average	Current Shares
Charles Brandes	2017-12-31	Reduce -1.09%		$2.74 - $3.51	$ 2.90	-6%	1,100,518
Barrow, Hanley, Mewhinney & Strauss	2017-12-31	Sold Out		$2.74 - $3.51	$ 2.90	-6%	0
Charles Brandes	2017-09-30	Add 0.48%		$2.17 - $3.4	$ 2.90	5%	1,112,679
Barrow, Hanley, Mewhinney & Strauss	2017-09-30	Reduce -8.61%		$2.17 - $3.4	$ 2.90	5%	23,201
Charles Brandes	2017-06-30	Add 1790.32%	0.05%	$2.02 - $2.59	$ 2.90	26%	1,107,310

More recent guru trades are included for Premium Members only!!

More recent guru trades are included for USA Subscribe Members only!!

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry:	Biotechnology » Biotechnology NAICS: 325412 SIC: 2836
Compare:	NAS:CYTK, SZSE:002566, XKRX:087010, XKRX:214450, XMCE:PHM, SZSE:002873, TSX:AUP, NAS:STML, OSTO:KARO, XKRX:182400, NAS:INO, NAS:PTGX, NAS:SIGA, NAS:INSY, NAS:GTXI, SHSE:603538, NAS:PRTK, SZSE:300653, NAS:KALA, OCSE:ZEAL » details
Traded in other countries:	PDL.Germany,
Headquarter Location:	USA

PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing value of its patent.

PDL BioPharma Inc discovers and develops humanized monoclonal antibodies and receives royalties from nine marketed products licensed under PDL patents. The ESP Pharma acquisition brought marketed products to PDL in 2005, but because of a lack of strategic fit, PDL sold its commercial assets in early 2008. After paying a special dividend to shareholders, PDL has spun off its drug-discovery and -development business and plans to continue distributing royalty-based income to shareholders.

Ratios

		vs industry	vs history
PE Ratio	4.04	PDLI's PE Ratio is ranked higher than 90% of the 260 Companies in the Global Biotechnology industry. ( Industry Median: 29.83 vs. PDLI: 4.04 ) Ranked among companies with meaningful PE Ratio only. =GURUF("PDLI","PE Ratio")	PDLI' s PE Ratio Range Over the Past 10 Years Min: 1.46 Med: 5.3 Max: 26.56 Current: 4.04 1.46 - 26.56 =GURUF("PDLI","PE Ratio")
Forward PE Ratio	33.11	PDLI's Forward PE Ratio is ranked lower than 61% of the 71 Companies in the Global Biotechnology industry. ( Industry Median: 24.45 vs. PDLI: 33.11 ) Ranked among companies with meaningful Forward PE Ratio only. =GURUF("PDLI","Forward PE Ratio")	N/A
PE Ratio without NRI	4.04	PDLI's PE Ratio without NRI is ranked higher than 91% of the 255 Companies in the Global Biotechnology industry. ( Industry Median: 30.45 vs. PDLI: 4.04 ) Ranked among companies with meaningful PE Ratio without NRI only. =GURUF("PDLI","PE Ratio without NRI")	PDLI' s PE Ratio without NRI Range Over the Past 10 Years Min: 1.46 Med: 5.01 Max: 26.56 Current: 4.04 1.46 - 26.56 =GURUF("PDLI","PE Ratio without NRI")
PB Ratio	0.52	PDLI's PB Ratio is ranked higher than 97% of the 954 Companies in the Global Biotechnology industry. ( Industry Median: 4.51 vs. PDLI: 0.52 ) Ranked among companies with meaningful PB Ratio only. =GURUF("PDLI","PB Ratio")	PDLI' s PB Ratio Range Over the Past 10 Years Min: 0.43 Med: 2.32 Max: 38.99 Current: 0.52 0.43 - 38.99 =GURUF("PDLI","PB Ratio")
PS Ratio	1.48	PDLI's PS Ratio is ranked higher than 91% of the 733 Companies in the Global Biotechnology industry. ( Industry Median: 9999.00 vs. PDLI: 1.48 ) Ranked among companies with meaningful PS Ratio only. =GURUF("PDLI","PS Ratio")	PDLI' s PS Ratio Range Over the Past 10 Years Min: 0.87 Med: 2.9 Max: 15.85 Current: 1.48 0.87 - 15.85 =GURUF("PDLI","PS Ratio")
Price-to-Free-Cash-Flow	12.36	PDLI's Price-to-Free-Cash-Flow is ranked higher than 91% of the 128 Companies in the Global Biotechnology industry. ( Industry Median: 33.20 vs. PDLI: 12.36 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. =GURUF("PDLI","Price-to-Free-Cash-Flow")	PDLI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years Min: 1.51 Med: 5.26 Max: 13.46 Current: 12.36 1.51 - 13.46 =GURUF("PDLI","Price-to-Free-Cash-Flow")
Price-to-Operating-Cash-Flow	11.93	PDLI's Price-to-Operating-Cash-Flow is ranked higher than 90% of the 196 Companies in the Global Biotechnology industry. ( Industry Median: 30.32 vs. PDLI: 11.93 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. =GURUF("PDLI","Price-to-Operating-Cash-Flow")	PDLI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years Min: 1.51 Med: 5.72 Max: 55.87 Current: 11.93 1.51 - 55.87 =GURUF("PDLI","Price-to-Operating-Cash-Flow")
EV-to-EBIT	0.78	PDLI's EV-to-EBIT is ranked higher than 92% of the 262 Companies in the Global Biotechnology industry. ( Industry Median: 24.43 vs. PDLI: 0.78 ) Ranked among companies with meaningful EV-to-EBIT only. =GURUF("PDLI","EV-to-EBIT")	PDLI' s EV-to-EBIT Range Over the Past 10 Years Min: 0.4 Med: 3.4 Max: 14.8 Current: 0.78 0.4 - 14.8 =GURUF("PDLI","EV-to-EBIT")
EV-to-EBITDA	0.66	PDLI's EV-to-EBITDA is ranked higher than 93% of the 287 Companies in the Global Biotechnology industry. ( Industry Median: 21.70 vs. PDLI: 0.66 ) Ranked among companies with meaningful EV-to-EBITDA only. =GURUF("PDLI","EV-to-EBITDA")	PDLI' s EV-to-EBITDA Range Over the Past 10 Years Min: 0.3 Med: 3.3 Max: 10.9 Current: 0.66 0.3 - 10.9 =GURUF("PDLI","EV-to-EBITDA")
EV-to-Revenue	0.51	PDLI's EV-to-Revenue is ranked higher than 98% of the 777 Companies in the Global Biotechnology industry. ( Industry Median: 13.46 vs. PDLI: 0.51 ) Ranked among companies with meaningful EV-to-Revenue only. =GURUF("PDLI","EV-to-Revenue")	PDLI' s EV-to-Revenue Range Over the Past 10 Years Min: 0.3 Med: 3.3 Max: 15.7 Current: 0.51 0.3 - 15.7 =GURUF("PDLI","EV-to-Revenue")
Shiller PE Ratio	2.44	PDLI's Shiller PE Ratio is ranked higher than 92% of the 79 Companies in the Global Biotechnology industry. ( Industry Median: 44.16 vs. PDLI: 2.44 ) Ranked among companies with meaningful Shiller PE Ratio only. =GURUF("PDLI","Shiller PE Ratio")	PDLI' s Shiller PE Ratio Range Over the Past 10 Years Min: 1.78 Med: 5.06 Max: 209.25 Current: 2.44 1.78 - 209.25 =GURUF("PDLI","Shiller PE Ratio")
Current Ratio	3.32	PDLI's Current Ratio is ranked lower than 60% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 4.21 vs. PDLI: 3.32 ) Ranked among companies with meaningful Current Ratio only. =GURUF("PDLI","Current Ratio")	PDLI' s Current Ratio Range Over the Past 10 Years Min: 0.26 Med: 9.88 Max: 57.61 Current: 3.32 0.26 - 57.61 =GURUF("PDLI","Current Ratio")
Quick Ratio	3.27	PDLI's Quick Ratio is ranked lower than 57% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 3.92 vs. PDLI: 3.27 ) Ranked among companies with meaningful Quick Ratio only. =GURUF("PDLI","Quick Ratio")	PDLI' s Quick Ratio Range Over the Past 10 Years Min: 0.26 Med: 9.88 Max: 57.61 Current: 3.27 0.26 - 57.61 =GURUF("PDLI","Quick Ratio")
Days Inventory	93.78	PDLI's Days Inventory is ranked lower than 54% of the 498 Companies in the Global Biotechnology industry. ( Industry Median: 126.17 vs. PDLI: 93.78 ) Ranked among companies with meaningful Days Inventory only. =GURUF("PDLI","Days Inventory")	PDLI' s Days Inventory Range Over the Past 10 Years Min: 71.9 Med: 100.69 Max: 129.48 Current: 93.78 71.9 - 129.48 =GURUF("PDLI","Days Inventory")
Days Sales Outstanding	37.65	PDLI's Days Sales Outstanding is ranked higher than 83% of the 656 Companies in the Global Biotechnology industry. ( Industry Median: 64.11 vs. PDLI: 37.65 ) Ranked among companies with meaningful Days Sales Outstanding only. =GURUF("PDLI","Days Sales Outstanding")	PDLI' s Days Sales Outstanding Range Over the Past 10 Years Min: 0.21 Med: 0.6 Max: 68.46 Current: 37.65 0.21 - 68.46 =GURUF("PDLI","Days Sales Outstanding")
Days Payable	236.48	PDLI's Days Payable is ranked higher than 85% of the 456 Companies in the Global Biotechnology industry. ( Industry Median: 62.86 vs. PDLI: 236.48 ) Ranked among companies with meaningful Days Payable only. =GURUF("PDLI","Days Payable")	PDLI' s Days Payable Range Over the Past 10 Years Min: 236.48 Med: 433.23 Max: 629.97 Current: 236.48 236.48 - 629.97 =GURUF("PDLI","Days Payable")

Buy Back

		vs industry	vs history
3-Year Dividend Growth Rate	-100.00	PDLI's 3-Year Dividend Growth Rate is ranked lower than 83% of the 88 Companies in the Global Biotechnology industry. ( Industry Median: 7.00 vs. PDLI: -100.00 ) Ranked among companies with meaningful 3-Year Dividend Growth Rate only. =GURUF("PDLI","3-Year Dividend Growth Rate")	PDLI' s 3-Year Dividend Growth Rate Range Over the Past 10 Years Min: 0 Med: 0 Max: -45 Current: -100 =GURUF("PDLI","3-Year Dividend Growth Rate")
5-Year Yield-on-Cost %	0.58	PDLI's 5-Year Yield-on-Cost % is ranked lower than 79% of the 308 Companies in the Global Biotechnology industry. ( Industry Median: 1.56 vs. PDLI: 0.58 ) Ranked among companies with meaningful 5-Year Yield-on-Cost % only. =GURUF("PDLI","5-Year Yield-on-Cost %")	PDLI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years Min: 0.54 Med: 2.19 Max: 5.71 Current: 0.58 0.54 - 5.71 =GURUF("PDLI","5-Year Yield-on-Cost %")
3-Year Average Share Buyback Ratio	1.60	PDLI's 3-Year Average Share Buyback Ratio is ranked higher than 72% of the 768 Companies in the Global Biotechnology industry. ( Industry Median: -13.20 vs. PDLI: 1.60 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. =GURUF("PDLI","3-Year Average Share Buyback Ratio")	PDLI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years Min: -7.9 Med: -5.5 Max: 1.6 Current: 1.6 -7.9 - 1.6 =GURUF("PDLI","3-Year Average Share Buyback Ratio")

Valuation & Return

		vs industry	vs history
Price-to-Net-Cash	3.33	PDLI's Price-to-Net-Cash is ranked higher than 75% of the 568 Companies in the Global Biotechnology industry. ( Industry Median: 8.85 vs. PDLI: 3.33 ) Ranked among companies with meaningful Price-to-Net-Cash only. =GURUF("PDLI","Price-to-Net-Cash")	PDLI' s Price-to-Net-Cash Range Over the Past 10 Years Min: 1.24 Med: 16.12 Max: 205.5 Current: 3.33 1.24 - 205.5 =GURUF("PDLI","Price-to-Net-Cash")
Price-to-Net-Current-Asset-Value	1.84	PDLI's Price-to-Net-Current-Asset-Value is ranked higher than 90% of the 695 Companies in the Global Biotechnology industry. ( Industry Median: 7.88 vs. PDLI: 1.84 ) Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only. =GURUF("PDLI","Price-to-Net-Current-Asset-Value")	PDLI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years Min: 1.22 Med: 5.73 Max: 41.53 Current: 1.84 1.22 - 41.53 =GURUF("PDLI","Price-to-Net-Current-Asset-Value")
Price-to-Tangible-Book	1.59	PDLI's Price-to-Tangible-Book is ranked higher than 87% of the 874 Companies in the Global Biotechnology industry. ( Industry Median: 5.88 vs. PDLI: 1.59 ) Ranked among companies with meaningful Price-to-Tangible-Book only. =GURUF("PDLI","Price-to-Tangible-Book")	PDLI' s Price-to-Tangible-Book Range Over the Past 10 Years Min: 0.99 Med: 3.09 Max: 31.88 Current: 1.59 0.99 - 31.88 =GURUF("PDLI","Price-to-Tangible-Book")
Price-to-Intrinsic-Value-Projected-FCF	0.17	PDLI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than 98% of the 179 Companies in the Global Biotechnology industry. ( Industry Median: 3.54 vs. PDLI: 0.17 ) Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only. =GURUF("PDLI","Price-to-Intrinsic-Value-Projected-FCF")	PDLI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years Min: 0.13 Med: 1.29 Max: 20.91 Current: 0.17 0.13 - 20.91 =GURUF("PDLI","Price-to-Intrinsic-Value-Projected-FCF")
Price-to-Median-PS-Value	0.52	PDLI's Price-to-Median-PS-Value is ranked higher than 81% of the 614 Companies in the Global Biotechnology industry. ( Industry Median: 1.00 vs. PDLI: 0.52 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. =GURUF("PDLI","Price-to-Median-PS-Value")	PDLI' s Price-to-Median-PS-Value Range Over the Past 10 Years Min: 0.36 Med: 3.94 Max: 22.55 Current: 0.52 0.36 - 22.55 =GURUF("PDLI","Price-to-Median-PS-Value")
Price-to-Graham-Number	0.53	PDLI's Price-to-Graham-Number is ranked higher than 91% of the 194 Companies in the Global Biotechnology industry. ( Industry Median: 2.76 vs. PDLI: 0.53 ) Ranked among companies with meaningful Price-to-Graham-Number only. =GURUF("PDLI","Price-to-Graham-Number")	PDLI' s Price-to-Graham-Number Range Over the Past 10 Years Min: 0.39 Med: 1.14 Max: 26.4 Current: 0.53 0.39 - 26.4 =GURUF("PDLI","Price-to-Graham-Number")
Earnings Yield (Greenblatt) %	129.87	PDLI's Earnings Yield (Greenblatt) % is ranked higher than 98% of the 1060 Companies in the Global Biotechnology industry. ( Industry Median: -6.86 vs. PDLI: 129.87 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. =GURUF("PDLI","Earnings Yield (Greenblatt) %")	PDLI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years Min: 6.8 Med: 29.6 Max: 265.1 Current: 129.87 6.8 - 265.1 =GURUF("PDLI","Earnings Yield (Greenblatt) %")
Forward Rate of Return (Yacktman) %	22.92	PDLI's Forward Rate of Return (Yacktman) % is ranked higher than 94% of the 135 Companies in the Global Biotechnology industry. ( Industry Median: 12.87 vs. PDLI: 22.92 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only. =GURUF("PDLI","Forward Rate of Return (Yacktman) %")	PDLI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years Min: -8.7 Med: 14.85 Max: 71.3 Current: 22.92 -8.7 - 71.3 =GURUF("PDLI","Forward Rate of Return (Yacktman) %")

More Statistics

Revenue (TTM) (Mil) $	302.32
EPS (TTM) $	0.72
Beta	0.30
Volatility	50.70%
52-Week Range $	2.01 - 3.55
Shares Outstanding (Mil)	153.81

Analyst Estimate

	Dec18
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($)	0.09
EPS without NRI ($)	0.09
EPS Growth Rate (Future 3Y To 5Y Estimate)	N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 7	7
Positive ROA	Y
Positive CFROA	Y
Higher ROA yoy	Y
CFROA > ROA	N
Lower Leverage yoy	Y
Higher Current Ratio yoy	Y
Less Shares Outstanding yoy	Y
Higher Gross Margin yoy	N
Higher Asset Turnover yoy	Y

» More Articles for NAS:PDLI

Headlines

Articles On GuruFocus.com

PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018 Apr 16 2018

PDL BioPharma Shareholder, SevenSaoi Capital, Comments on the Nomination of Shlomo Yanai to the PDL Apr 09 2018

PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference Apr 03 2018

PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018 Mar 01 2018

Neos Therapeutics Reiterates Confidence in Strategic Plan and Value Creation Opportunities Feb 20 2018

PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos Feb 20 2018

PDL BioPharma to Present at Two Upcoming Investor Conferences Feb 14 2018

9 Positions Charles Brandes Increased in the Past 2 Quarters Nov 15 2017

Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hyper Nov 15 2017

Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell Intern Nov 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

Value Screens

Downloads | Tools

Strategies

Market Valuation

By Country

Articles

Submit Articles